Market Place
Sourcing Support
Faron presents Bexmab data at ASH Annual Meeting
10 Dec 2024 //
PR NEWSWIRE
Faron`s bexmarilimab Developers Named European Inventor Award Finalists
16 May 2024 //
GLOBENEWSWIRE
Faron Confirms Plans for the Coming Months Under New Leadership
16 Apr 2024 //
GLOBENEWSWIRE
Inside Information: Additional Positive Data from the Ph1 Part of BEXMAB Study
18 Mar 2024 //
GLOBENEWSWIRE
Positive Data from the Ph1 Part of the BEXMAB Study Failed
18 Mar 2024 //
GLOBENEWSWIRE
Faron to Host Webcast to Discuss data from Phase 1 of Study of Bexmarilimab
14 Mar 2024 //
GLOBENEWSWIRE
Faron™s Financial Statement Release January 1 to December 31, 2023
13 Mar 2024 //
GLOBENEWSWIRE
Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population
25 Jan 2024 //
GLOBENEWSWIRE
Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab
09 Jan 2024 //
GLOBENEWSWIRE
Faron Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial
11 Dec 2023 //
GLOBENEWSWIRE
Faron Announces Publication of Full Analysis from Phase 1/2 of Bexmarilimab
07 Dec 2023 //
GLOBENEWSWIRE
Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS
06 Nov 2023 //
GLOBENEWSWIRE
Faron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab
02 Nov 2023 //
GLOBENEWSWIRE
Announcement of the Results of Placing, the Issue Price with the Trade Register
27 Oct 2023 //
GLOBENEWSWIRE
Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML
11 Oct 2023 //
GLOBENEWSWIRE
Faron to Host Webcast to Discuss Data From Phase I/II Study of Bexmarilimab
02 Oct 2023 //
GLOBENEWSWIRE
Faron Pharmaceuticals Announces Board Changes
22 Sep 2023 //
GLOBENEWSWIRE
Faron Appoints Dr. Birge Berns, MD as Interim Chief Medical Officer
21 Sep 2023 //
GLOBENEWSWIRE
Faron to Present at the H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
Faron Receives FDA Orphan Drug Designation for Bexmarilimab in AML
29 Aug 2023 //
GLOBENEWSWIRE
Faron Reports Half-Year Financial Results, January 1 June 30, 2023
29 Aug 2023 //
GLOBENEWSWIRE
Faron Pharmaceuticals Notice of Half-Year Financial Results
04 Aug 2023 //
GLOBENEWSWIRE
Faron to Participate in Fireside Chat at the Canaccord Genuity Annual Conference
02 Aug 2023 //
GLOBENEWSWIRE
Faron to Hold Conference to Discuss Data from Phase I/II Study of Bexmarilimab
19 Jul 2023 //
GLOBENEWSWIRE
Faron`s latest snapshot suggests antibody has leukemia potential
19 Jul 2023 //
FIERCE BIOTECH
New biomarker data from BEXMAB study at EHA2023
09 Jun 2023 //
PR NEWSWIRE
Faron Appoints Maija Hollmén as CSO
01 Dec 2022 //
CISION
Faron Names Dr. Maija Hollmén as Chief Scientific Officer
01 Dec 2022 //
CONTRACTPHARMA
Faron Pharmaceuticals hails potential of cancer immunotherapy
19 Sep 2022 //
PROACTIVEINVESTORS
Presentation of Biomarker Analysis at ASCO
30 May 2022 //
PRNEWSWIRE
Faron Announces FDA and FMA Approval to Initiate PI/II Bexmarilimab
16 May 2022 //
PRNEWSWIRE
Faron Presents Results from Melanoma Cohort of MATINS Trial at 18th Congress
21 Apr 2022 //
PRNEWSWIRE
Financial Statement January 1 to December 31 2021
24 Mar 2022 //
PRNEWSWIRE
UK Health Secretary: rise in COVID-19 cases ‘expected’
14 Mar 2022 //
PHARMAFILE
Presentation of Biomarker Data at AACR
09 Mar 2022 //
PRNEWSWIRE
Faron Updates on Bexmarilimab Development Program
22 Feb 2022 //
PRNEWSWIRE
Faron Announces R&D Day
14 Feb 2022 //
PRNEWSWIRE
Faron announces new COO to catapult cancer immunotherapy development
31 Jan 2022 //
PROACTIVEINVESTORS
Faron Announces Topline MATINS Biomarker Analysis
09 Dec 2021 //
PRNEWSWIRE
Faron raises over €10mln to support key drug candidates
30 Sep 2021 //
PHARMAFILE
Presentation of Updated MATINS Data at ESMO
17 Sep 2021 //
CISION
Faron Announces Presentation of Bexmarilimab Data From Ongoing MATINS Trial
09 Sep 2021 //
INVESTIGATE
Faron Pharmaceuticals Doses First Patient in Phase II/III HIBISCUS Trial
25 Aug 2021 //
CISION
US rights to patent related to Traumakine
14 May 2021 //
CISION
Bexmarilimab (Clevegen) development update
20 Jan 2021 //
CISION
Faron Pharmaceuticals says US Department of Defense gets behind
18 Jan 2021 //
PROACTIVEINVESTORS
Farn Pharmaceutical 2020 half year report
24 Sep 2020 //
INVESTEGATE
Faron Pharma. Oy Traumakine Update
18 Aug 2020 //
INVESTEGATE
Faron Pharma Oy Harmful association of glucocorticoids in interferon beta-1a
20 May 2020 //
CISION
Faron Pharmaceuticals chief hails as crucial new data unexpected phIII result
19 May 2020 //
PROTECTIVEINVESTOR
Faron receives grant from Business Finland
12 May 2020 //
INVESTIS
AGC Biologics Partners with Faron Pharmaceuticals to Manufacture Cancer
05 May 2020 //
PR NEWSWIRE
